Moleculin Biotech Investor Relations Material
Latest events
Q1 2024
Moleculin Biotech
Access the full event backlog
Slides, Transcripts, and Reports from 9,000+ public companies
Latest reports from Moleculin Biotech Inc
Access all reports
Moleculin Biotech, Inc. (MBRX) is a clinical-stage pharmaceutical company aiming to develop treatments addressing some of the most challenging diseases in the world, including highly resistant cancers and viruses. The company's lead drug, Annamycin, is a next-generation anthracycline designed to overcome multidrug resistance with minimal cardiotoxicity, currently under development for relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma (STS) lung metastases. Additionally, Moleculin is working on WP1066, an Immune/Transcription Modulator targeting brain tumors, pancreatic cancer, and other malignancies, alongside WP1220 for cutaneous T-cell lymphoma and WP1122, aimed at treating COVID-19 and glioblastoma multiforme, among other conditions. The company is headquartered in Houston, Texas, and its shares are listed on the Nasdaq.
Latest articles
The Birkin Bag: The Story Behind the World's Most Desired Handbag
How the Birkin bag became the world's most sought-after handbag where even the wealthy must earn the right to own one.
12 Jul 2024
The 10 Largest Semiconductor Companies in the World
Discover the top 10 semiconductor companies by market cap, exploring their innovations and business models shaping the tech landscape.
10 Jul 2024
The Rise of Nubank: Changing Latin American Finance
Discover how Nubank revolutionized Latin American banking with innovation, backed by top investors like Berkshire Hathaway.
9 Jul 2024
Ticker symbol
MBRX
Country
đșđž United States